Skip to main content
Midas Edge

Stoke Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 3, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 3, 2026

STOK$27.21-1.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed consolidated statements of operations and comprehensive (loss) income

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue$9,325$13,817$15,554$172,386
Operating expenses:
Research and development49,50125,85589,17458,531
Sales, general and administrative25,25315,26245,22729,915
Total operating expenses74,75441,117134,40188,446
(Loss) income from operations(65,429)(27,300)(118,847)83,940
Other income (expense):
Interest income (expense), net3,5033,7896,8996,678
Other income3082832757
Total other income (expense)3,8113,8177,2266,735
(Loss) income before income taxes$(61,618)$(23,483)$(111,621)$90,675
Provision for income taxes———1,278
Net (loss) income$(61,618)$(23,483)$(111,621)$89,397
Net (loss) income per share:
Basic$(0.93)$(0.40)$(1.73)$1.54
Diluted(0.93)(0.40)(1.73)1.50
Weighted-average common shares outstanding:
Basic66,017,89558,353,85564,548,86258,109,622
Diluted66,017,89558,353,85564,548,86259,681,472
Comprehensive (loss) income:
Net (loss) income$(61,618)$(23,483)$(111,621)$89,397
Other comprehensive (loss) gain:
Unrealized (loss) gain on marketable securities(427)200(1,085)247
Total other comprehensive (loss) gain$(427)$200$(1,085)$247
Comprehensive (loss) income$(62,045)$(23,283)$(112,706)$89,644

Condensed consolidated statements of stockholders’ equity

Common Stock · Additionalpaid-in capital · Accumulated other comprehensive gain (loss) · Accumulateddeficit · Total stockholders’equity
Shares · Amount
Balance as of December 31, 202454,032,826$5$719,997$(151)$(490,830)$229,021
Unrealized gain on marketable securities———47—47
Stock-based compensation——6,753——6,753
Issuance of common stock upon exercise of stock options214,996—1,004——1,004
Issuance of common stock related to employee stock purchase plan39,467—370——370
Issuance of vested restricted and performance stock units308,425—————
Net income————112,879112,879
Balance as of March 31, 202554,595,714$5$728,124$(104)$(377,951)$350,074
Unrealized gain on marketable securities———200—200
Stock-based compensation——7,598——7,598
Issuance of common stock upon exercise of stock options126,531—554——554
Issuance of vested restricted and performance stock units1,210—————
Net loss————(23,483)(23,483)
Balance as of June 30, 202554,723,455$5$736,276$96$(401,434)$334,943
Balance as of December 31, 202558,921,999$5$849,624$543$(497,715)$352,457
Unrealized (loss) on marketable securities———(658)—(658)
Stock-based compensation——8,753——8,753
Issuance of common stock upon exercise of stock options260,554—3,205——3,205
Issuance of common stock related to employee stock purchase plan46,994465——465
Issuance of vested restricted and performance stock units443,786—————
Shares sold as part of controlled equity offering sales agreement2,567,014180,657——80,658
Net loss————(50,003)(50,003)
Balance as of March 31, 202662,240,347$6$942,704$(115)$(547,718)$394,877
Unrealized (loss) on marketable securities———(427)—(427)
Stock-based compensation——10,802——10,802
Issuance of common stock upon exercise of stock options162,248—1,913——1,913
Net loss————(61,618)(61,618)
Balance as of June 30, 202662,402,595$6$955,419$(542)$(609,336)$345,547
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.